Close Menu

NEW YORK – Becton Dickinson revealed last week that it has acquired NAT Diagnostics, a molecular diagnostics firm focused on rapid point-of-care testing. The NAT Dx isothermal technology will be further developed by BD with an eye toward offering customers decentralized molecular testing options in early 2023.

The deal was signed last year, according to BD, but it was not finalized until last quarter. Terms of the agreement have not been disclosed.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.